NASDAQ · KMTS
Healthcare · Medical - Instruments & Supplies
$25.81
Down-$0.76 (-2.86%)
Updated Aug 28, 2026, 12:05 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
KMTS closed at $25.81 after 21 trading sessions, up 11.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $26.56 | $27.244 | $25.78 | $25.81 | 198.31K |
| Aug 26, 2026 | $26.64 | $26.99 | $26.07 | $26.57 | 210.77K |
| Aug 25, 2026 | $27.24 | $27.5012 | $26.49 | $26.92 | 159.56K |
| Aug 24, 2026 | $26.98 | $27.53 | $26.24 | $26.91 | 171.36K |
| Aug 21, 2026 | $27.41 | $27.455 | $26.31 | $26.99 | 510.81K |
| Aug 20, 2026 | $27.49 | $28.11 | $27.00 | $27.26 | 246.91K |
| Aug 19, 2026 | $28.31 | $28.89 | $27.66 | $27.91 | 237.66K |
| Aug 18, 2026 | $27.55 | $28.33 | $26.69 | $27.93 | 249.3K |
| Aug 17, 2026 | $27.52 | $28.02 | $26.90 | $27.82 | 193.75K |
| Aug 14, 2026 | $27.37 | $28.185 | $26.5249 | $28.02 | 179.48K |
| Aug 13, 2026 | $28.18 | $28.61 | $27.50 | $27.74 | 347.94K |
| Aug 12, 2026 | $27.76 | $28.585 | $27.53 | $28.00 | 406.14K |
| Aug 11, 2026 | $28.56 | $28.75 | $27.676 | $27.90 | 225.98K |
| Aug 10, 2026 | $26.90 | $28.70 | $26.70 | $28.35 | 352.18K |
| Aug 7, 2026 | $25.61 | $26.47 | $25.09 | $26.40 | 275.73K |
| Aug 6, 2026 | $24.55 | $25.46 | $24.33 | $25.27 | 184.87K |
| Aug 5, 2026 | $25.68 | $26.065 | $24.69 | $25.06 | 350.95K |
| Aug 4, 2026 | $24.05 | $26.03 | $23.90 | $25.93 | 731.24K |
| Aug 3, 2026 | $23.19 | $24.24 | $23.19 | $23.99 | 373.73K |
| Jul 31, 2026 | $23.38 | $24.065 | $22.11 | $22.83 | 277.95K |
| Jul 30, 2026 | $22.91 | $23.9999 | $22.22 | $23.15 | 283.75K |
The latest Smart Investors Daily articles mentioning KMTS.
KMTS research
Company profile and research snapshot.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | JP Morgan | Overweight | — |
| Jul 21, 2026 | Oppenheimer | Perform | — |
| Jul 15, 2026 | BTIG | Buy | — |
| Apr 9, 2026 | Goldman Sachs | Neutral | — |
| Apr 7, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Analysts changed ratings for GWRE, KMTS, CSQR, and STDN. See coverage details and price targets at Benzinga's analyst ratings page.
Benzinga · Aug 10, 2026
JP Morgan analyst Robbie Marcus initiates coverage on Kestra Medical Techs (NASDAQ:KMTS) with a Overweight rating and announces Price Target of $30.
Benzinga · Jul 21, 2026
Oppenheimer analyst Suraj Kalia initiates coverage on Kestra Medical Techs (NASDAQ:KMTS) with a Perform rating.
Benzinga · Jul 15, 2026
BTIG analyst Marie Thibault maintains Kestra Medical Techs (NASDAQ:KMTS) with a Buy and raises the price target from $30 to $32.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KMTS.
